🇺🇸 FDA

Company profile · Sponsor

X4

X4 Pharmaceuticals, Inc

XFOR · NYSE biotech BOSTON, MA, USA
Pipeline
11
Drugs
0
Patents
8

Quick answer

X4 (XFOR) is a biotech company. headquartered in BOSTON, MA, USA. listed on NYSE. NovaPharmaNews links 11 pipeline programs, 0 drugs, and 8 patents to this profile..

Company facts

Ticker XFOR
Exchange NYSE
Company type biotech
Headquarters BOSTON, MA, USA
SEC CIK 0001501697

Pipeline (11)

Search pipeline →

  1. Mavorixafor

    X4

    Neutropenia

    phase 3 small molecule active

    2 trials

  2. Mavorixafor

    X4

    WHIM Syndrome

    phase 3 small molecule active

    1 trial

  3. Mavorixafor, Mavorixafor Placebo Capsules

    X4

    Neutropenias

    phase 3 small molecule active

    1 trial

  4. Mavorixafor, Placebo to Test IMP

    X4

    WHIM Syndrome

    phase 3 small molecule active

    1 trial

  5. X4P-001

    X4

    WHIM Syndrome

    phase 2 small molecule completed

    1 trial

  6. X4P-001

    X4

    Clear Cell Renal Cell Carcinoma

    phase 2 small molecule completed

    2 trials

  7. Mavorixafor

    X4

    Hepatic Insufficiency

    phase 1 small molecule active

    1 trial

  8. Mavorixafor

    X4

    Healthy Participants

    phase 1 small molecule completed

    1 trial

  9. Mavorixafor

    X4

    Waldenstrom's Macroglobulinemia

    phase 1 small molecule completed

    1 trial

  10. X4P-001

    X4

    Healthy

    phase 1 small molecule terminated

    1 trial

  11. X4P-001

    X4

    Melanoma

    phase 1 small molecule completed

    1 trial

Patents (8)

Search patents →

  1. US 12377090

    Methods for treating neutropenia

    Expires Mon Jul 31 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12285424

    Methods for treating neutropenia

    Expires Mon Apr 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12115156

    Compositions of CXCR4 inhibitors and methods of preparation and use

    Expires Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11780837

    CXCR4 inhibitors and uses thereof

    Expires Mon Oct 05 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11672793

    Compositions of CXCR4 inhibitors and methods of preparation and use

    Expires Mon Jun 08 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11357742

    Methods for treating cancer

    Expires Mon Jun 09 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11337969

    Methods for treating cancer

    Expires Mon May 19 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11332470

    CXCR4 inhibitors and uses thereof

    Expires Mon May 12 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is X4?

X4 (XFOR) is a biotech company. headquartered in BOSTON, MA, USA. listed on NYSE. NovaPharmaNews links 11 pipeline programs, 0 drugs, and 8 patents to this profile..

What pipeline programs does X4 sponsor?

We track 11 ClinicalTrials.gov-linked programs for X4, including Mavorixafor and 10 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does X4 company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.